Flash glucose monitoring (FGM) reduced HbA1c by 0.44% compared to standard capillary blood glucose monitoring in Indian youth with type 1 diabetes, with greater improvements in those starting with higher glucose levels.
Researchers at centers in Ahmedabad, India conducted a 12-month randomized crossover trial comparing two glucose monitoring methods in 106 young people (aged 10-25 years) with type 1 diabetes lasting at least one year. Half started with the Freestyle Libre flash glucose monitor for 6 months before switching to standard self-monitoring of blood glucose (SMBG) via finger pricks at least 4 times daily. The other half did the reverse. This design allowed each participant to serve as their own control, reducing confounding variables like individual insulin sensitivity or dietary patterns.
The headline finding was straightforward: when using FGM, participants achieved an HbA1c reduction of 0.44% (4.8 mmol/mol) compared to SMBG (p=0.006). This difference persisted across both crossover orders, suggesting the effect was genuine rather than a carryover artifact. The magnitude matters in context. An 0.44% reduction translates to meaningful long-term glucose control improvement, as each 1% reduction in HbA1c is associated with reduced microvascular complications in type 1 diabetes. The effect was not uniform: individuals with higher baseline HbA1c (worse control) saw greater absolute improvements when switching to FGM (p=0.003), suggesting the technology may be most beneficial for those struggling with conventional monitoring.
The study revealed a pattern worth examining closely. In the group that used FGM first, HbA1c dropped from 8.6% to 7.9% during the FGM phase, then remained relatively stable when they switched back to SMBG (staying around 7.9-8.1%). In the group starting with SMBG, glucose control initially remained stagnant at 8.6-8.8%, but improved to 8.3% once they switched to FGM. This suggests FGM enabled meaningful glucose optimization that persisted even after returning to SMBG, possibly reflecting behavioral changes in insulin dosing or dietary awareness that participants maintained. Notably, both groups entered a 6-month observation period at month 12 where they could choose their preferred monitoring method, though final outcomes from this phase weren't detailed.
The study enrolled participants from a low-resource setting where technology access and healthcare infrastructure differ substantially from high-income countries. Baseline HbA1c of 8.6% indicates suboptimal control by clinical standards, though not unusual for youth with type 1 diabetes globally. The 86% completion rate (91 of 106 participants) is respectable for a 12-month pediatric study. The relatively balanced gender distribution (47% female) and documented diabetes duration (mean 9.9 years) suggest a stable, established patient population rather than newly diagnosed individuals still in the honeymoon phase.
If you or someone you care for has type 1 diabetes and uses capillary blood glucose monitoring, this evidence supports considering FGM as a next step if access and cost permit. The improvement appears most pronounced when baseline glucose control is higher (HbA1c above 8%), which matches clinical experience that better monitoring visibility drives behavioral change when control is suboptimal.
The practical value extends beyond the numbers. Flash glucose monitors reduce finger-stick testing from 4+ daily to scanning a sensor, lowering burden and potentially improving adherence in younger people who may find frequent testing burdensome. The improved glycemic outcomes might reflect better decision-making enabled by continuous glucose trend data rather than just point-in-time measurements.
However, this study's findings shouldn't be overstated. The 0.44% reduction is clinically meaningful but modest. The study was conducted in India with local insulin and dietary management standards; results may not perfectly translate to different healthcare systems. No quality-of-life metrics, psychological burden scores, or cost-effectiveness analyses were reported, which limits understanding of the full patient experience. Real-world adoption depends on affordability and supply chain reliability, which remain challenging in many settings.
For healthcare systems evaluating whether to fund FGM for young people with type 1 diabetes, this provides evidence of benefit from a relevant population (low-resource setting, suboptimal baseline control). For individuals deciding whether FGM is worth pursuing, the consistent 0.44% HbA1c improvement across different baseline characteristics and both crossover orders suggests a reliable benefit, even if modest.
| Parameter | Details |
|---|---|
| Study type | Randomized controlled crossover trial |
| Sample size | 106 enrolled; 91 (86%) completed 12-month follow-up |
| Participant age | 10-25 years (mean 17.8 years) |
| Diabetes duration | Mean 9.9 years (established T1D) |
| Baseline HbA1c | 8.6% (70 mmol/mol) |
| Intervention | Freestyle Libre 1 flash glucose monitor (6 months) |
| Comparison | Self-monitoring of blood glucose via capillary sampling (6 months) |
| Primary outcome | HbA1c measured at 0, 3, 6, 9, and 12 months |
| Main finding | HbA1c reduction of 0.44% (4.8 mmol/mol) with FGM vs SMBG (p=0.006) |
| Effect modifier | Greater improvement in those with higher baseline HbA1c (p=0.003) |
| Location | Ahmedabad, India (low-resource setting) |
| Journal | BMJ Paediatrics Open |
| Publication date |
Desai, S., et al. "Impact of flash glucose monitoring versus capillary blood glucose monitoring on glycaemia in Indian youth with type 1 diabetes: a randomised crossover study." *BMJ Paediatrics Open*, 2024. PubMed: 42215031
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.
| Trial registration | CTRI/2022/02/020175 |